Clear­side shares jump as re­for­mu­lat­ed TKI drug pass­es mid-stage test in wet AMD

Clear­side Bio­med­ical re­port­ed pos­i­tive re­sults from a Phase 2b tri­al of its ty­ro­sine ki­nase in­hibitor in pa­tients with wet age-re­lat­ed mac­u­lar de­gen­er­a­tion, bol­ster­ing its prospects …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER